PRPeter H. Reinhart

Peter H. Reinhart

*This is an algorithmically generated author record based on publicly available information.

Peter H. Reinhart has a total of 138 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Population-based serosurveys for SARS-CoV-2 transmission 2021-2022, Massachusetts USA

    by Estee Y. Cramer, Augustine O. Dada, Shauna Onofrey, Jessica Pearlman, John Cluverius, Rebecca Loveland, Ashley Eaton, Megan Hatch, Lily Harris, Joshua Dyck, et al.

    Background: SARS-CoV-2 has been responsible for extensive morbidity and mortality in Massachusetts, especially from 2021 – 2022. The true burden of infection is unknown as official reporting data during 2021 and 2022 was not able to capture subclinical/asymptomatic infections nor the results from home-based lateral flow tests (LFTs). Aim: This study was designed to better characterize the exposure of Massachusetts residents to SARS-CoV-2, and to understand demographic and behavioral factors associated with SARS-CoV-2 exposure during the highest burden years of the pandemic. Methods: A series of five sequential state-wide serosurveys were conducted with oversampling for underrepresented demographic groups from June 2021 to September 2022. These mail-based, repeated cross-sectional surveys (RCSs) captured data at periods of rapid vaccine uptake when different viral variants were predominant. This study also included collection of at-home nasal swabs for PCR-based SARS-CoV-2 virological testing, and collection of dried blood spot cards for ELISA-based testing of SARS-CoV-2 IgG antibody markers including spike and capsid, reported as seroprevelences. Neutralizing antibodies to spike-RBD were also measured. Results: Of the randomly selected 249,000 Massachusetts households invited to participate in this survey, a total of 2,220 participants completed the demographic questionnaire and submitted valid specimens for analysis. Of these participants, ten were PCR-positive for SARS-CoV-2 at time of survey. Across all five repeated cross-sectional surveys (RCS), spike antibody positivity ranged from 83.1% to 96.4%. Additionally, levels of the spike neutralizing antibody increased with each RCS; point prevalence values ranged from 20.5% in RCS 1 and 2 to 73.5% in RCS 5. Using weighted data, the seroprevalence of capsid remained relatively constant throughout the RCSs except for RCS 3. Multivariable regression results found a positive association between vaccination status and markers of SARS-CoV-2 exposure; individuals who had been vaccinated were more likely to be seropositive for all markers. Factors including race, age, income, and occupation did not show any statistically significant associations with serostatus. Conclusions: This survey indicates that while there was an increase in antibodies to spike protein and to associated neutralizing antibodies over time, there were no differences in neutralizing antibodies by socio-demographic factors, suggesting no major health disparities existed at the time of surveys in either vaccine coverage or infection-related antibody titers across the state. Response rates were higher among some demographic groups (Caucasians, households with a high income, and women), thus, oversampling and weighting allowed estimates of the larger Massachusetts population. Our findings that there were no statistically significant differences in neutralizing antibodies across demographic groups suggesting all groups were similarly protected from SARS-CoV-2 infection. These results highlight the success of Massachusetts in protecting individuals across all demographics.

  • Potent α-Synuclein Aggregation Inhibitors, Identified by High-Throughput Screening, Mainly Target the Monomeric State

    by Martin Kurnik, Cagla Sahin, Camilla Bertel Andersen, Nikolai Lorenzen, Lise Giehm, Hossein Mohammad-Beigi, Christian Moestrup Jessen, Jan Skov Pedersen, Gunna Christiansen, Steen Vang Petersen, et al.


  • Open Access

    Sodium Channel Cleavage Is Associated with Aberrant Neuronal Activity and Cognitive Deficits in a Mouse Model of Alzheimer's Disease

    by Brian F. Corbett, Steven C. Leiser, Huai-Ping Ling, Reka Nagy, Nathalie Breysse, Xiaohong Zhang, Anupam Hazra, Jon T. Brown, Andrew D. Randall, Andrew Wood, et al.

    BACE1 is the rate-limiting enzyme that cleaves amyloid precursor protein (APP) to produce the amyloid β peptides that accumulate in Alzheimer's disease (AD). BACE1, which is elevated in AD patients and APP transgenic mice, also cleaves the β2-subunit of voltage-gated sodium channels (Navβ2). Although increased BACE1 levels are associated with Navβ2 cleavage in AD patients, whether Navβ2 cleavage occurs in APP mice had not yet been examined. Such a finding would be of interest because of its potential impact on neuronal activity: previous studies demonstrated that BACE1-overexpressing mice exhibit excessive cleavage of Navβ2 and reduced sodium current density, but the phenotype associated with loss of function mutations in either Navβ-subunits or pore-forming α-subunits is epilepsy. Because mounting evidence suggests that epileptiform activity may play an important role in the development of AD-related cognitive deficits, we examined whether enhanced cleavage of Navβ2 occurs in APP transgenic mice, and whether it is associated with aberrant neuronal activity and cognitive deficits. We found increased levels of BACE1 expression and Navβ2 cleavage fragments in cortical lysates from APP transgenic mice, as well as associated alterations in Nav1.1α expression and localization. Both pyramidal neurons and inhibitory interneurons exhibited evidence of increased Navβ2 cleavage. Moreover, the magnitude of alterations in sodium channel subunits was associated with aberrant EEG activity and impairments in the Morris water maze. Together, these results suggest that altered processing of voltage-gated sodium channels may contribute to aberrant neuronal activity and cognitive deficits in AD.


  • Early cerebrovascular inflammation in a transgenic mouse model of Alzheimer's disease

    by Dongzi Yu, Brian Corbett, Yaping Yan, Guang-Xian Zhang, Peter Reinhart, Seongeun J. Cho, Jeannie Chin


  • Identification of anti-inflammatory targets for Huntington's disease using a brain slice-based screening assay

    by Peter H. Reinhart, Linda S. Kaltenbach, Christian Essrich, Denise E. Dunn, Joshua A. Eudailey, C. Todd DeMarco, Gregory J. Turmel, Jennifer C. Whaley, Andrew Wood, Seongeun Cho, et al.


  • Treating the Periphery to Ameliorate Neurodegenerative Diseases

    by Peter H. Reinhart, Jeffery W. Kelly


  • Design and synthesis of aminohydantoins as potent and selective human β-secretase (BACE1) inhibitors with enhanced brain permeability

    by Michael S. Malamas, Albert Robichaud, Jim Erdei, Dominick Quagliato, William Solvibile, Ping Zhou, Koi Morris, Jim Turner, Erik Wagner, Kristi Fan, et al.


  • Open Access

    Identification and Characterization of a Leucine-Rich Repeat Kinase 2 (LRRK2) Consensus Phosphorylation Motif

    by Pooja P. Pungaliya, Yuchen Bai, Kerri Lipinski, Vasanti S. Anand, Saurabh Sen, Eugene L. Brown, Brian Bates, Peter H. Reinhart, Andrew B. West, Warren D. Hirst, et al.

    Mutations in LRRK2 (leucine-rich repeat kinase 2) have been identified as major genetic determinants of Parkinson's disease (PD). The most prevalent mutation, G2019S, increases LRRK2's kinase activity, therefore understanding the sites and substrates that LRRK2 phosphorylates is critical to understanding its role in disease aetiology. Since the physiological substrates of this kinase are unknown, we set out to reveal potential targets of LRRK2 G2019S by identifying its favored phosphorylation motif. A non-biased screen of an oriented peptide library elucidated F/Y-x-T-x-R/K as the core dependent substrate sequence. Bioinformatic analysis of the consensus phosphorylation motif identified several novel candidate substrates that potentially function in neuronal pathophysiology. Peptides corresponding to the most PD relevant proteins were efficiently phosphorylated by LRRK2 in vitro. Interestingly, the phosphomotif was also identified within LRRK2 itself. Autophosphorylation was detected by mass spectrometry and biochemical means at the only F-x-T-x-R site (Thr 1410) within LRRK2. The relevance of this site was assessed by measuring effects of mutations on autophosphorylation, kinase activity, GTP binding, GTP hydrolysis, and LRRK2 multimerization. These studies indicate that modification of Thr1410 subtly regulates GTP hydrolysis by LRRK2, but with minimal effects on other parameters measured. Together the identification of LRRK2's phosphorylation consensus motif, and the functional consequences of its phosphorylation, provide insights into downstream LRRK2-signaling pathways.


  • Inhibition of c-Jun kinase provides neuroprotection in a model of Alzheimer's disease

    by Steven P. Braithwaite, Ralf S. Schmid, Dong Ning He, Mei-Li A. Sung, Seongeon Cho, Lynn Resnick, Michael M. Monaghan, Warren D. Hirst, Christian Essrich, Peter H. Reinhart, et al.


  • Pyridinyl aminohydantoins as small molecule BACE1 inhibitors

    by Ping Zhou, Yanfang Li, Yi Fan, Zheng Wang, Rajiv Chopra, Andrea Olland, Yun Hu, Ronald L. Magolda, Menelas Pangalos, Peter H. Reinhart, et al.